摘要
手术和化疗是治疗上皮性卵巢癌的两大主要治疗手段,满意的肿瘤细胞减灭术是化疗成功的关键。上皮性卵巢癌复发率高达80%,化疗耐药是本病复发的根本原因。吉西他滨于2006年由美国食品药品监督管理局(Food and Drug Administration,FDA)批准用于停铂治疗半年后复发的卵巢癌患者的新化疗药物。本文聚焦该药近年来在上皮性卵巢癌中的应用及研究进展,现综述如下。
Surgery and chemotherapy are the two main measures to treat epithelial ovarian cancer （EOC）, and sarisfled cytoreduetive surgery is the key precondition of successful chemotherapy. Although new drugs or regimens emerge constantly, incidence of recurrence of epithelial ovarian cancer reaches up to 80%, however, chemotherapy resistance is the basic reason of the recurrence. Even though, some of these drugs or regimens bring about some promise to patients with epithelial ovarian cancer. Gemcitabine has been approved to apply to chemotherapy of patients with recurrent epithelial ovarian cancer whose platinum-free interval is more than 6 months by Food and Drug Administration （FDA） in the year of 2006. We reviewed its current application and development in epithelial ovarian cancer in recent years as followed.
出处
《中华妇幼临床医学杂志（电子版）》
CAS
2009年第5期65-69,共5页
Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)
关键词
卵巢癌
化疗
吉西他滨
epithelial ovarian cancer（EOC）
chemotherapy
gemcitabine
